Why Inflammation Detection Matters
"Early detection of inflammation is crucial, as it often precedes plaque buildup and provides a critical window for preventing disease," said Dr. Michael Doney, Executive Medical Director of Biograph. "By engaging in such a partnership with Caristo, we're better suited to position our members at the forefront of cardiac diagnostics, providing research access to a technology not yet broadly available in the U.S."
Current clinical pathways often fail to identify high risk patients by missing inflammatory disease activity and relying on plaque assessment alone. In fact, twice as many fatal and non-fatal cardiac events occurred in patients without obstructive plaque on coronary computed tomography angiography (CCTA), with CaRi-Heart able to identify these patients up to 10 years in advance, even in the absence of visible plaque [Lancet, 2024]. CaRi-Heart technology is a major breakthrough because it quantifies 'invisible' coronary inflammation on cardiac CT scans, rather than having to wait for patients to develop visible plaque. The CaRi-Heart technology is already approved for use in Europe, and this study will be its first evaluation for U.S. research applications in asymptomatic patients traditionally seen as low risk.
"We selected Biograph as our first U.S. longevity focused partner because of its preventive focus, data-driven approach, and advanced imaging capabilities. With Biograph's highly engaged patient population, this is an ideal partnership to demonstrate the impact of CaRi-Heart technology for early detection and the benefits of long-term heart health," said Professor Keith Channon, Chief Medical Officer of Caristo Diagnostics and Professor of Cardiovascular Medicine at the University of Oxford.
Study Design and Participant Experience
In the initial phase the study will enroll 100 of Biograph's Black Tier members beginning in October. Eligible participants will complete a health history form and consultation before imaging to ensure suitability for the study. Findings are expected to corroborate Caristo's existing studies with CaRi-Heart, in their continued efforts to make early detection available globally.
For Biograph, this initiative supports their ongoing mission to revolutionize healthcare and champion preventive approaches.
For more details on the partnership or to request enrollment in the study, visit www.biograph.com.
About Biograph
Biograph is on a mission to drive meaningful advances in human healthspan and lifespan. We've created the world's most advanced preventive health and diagnostics clinic, where an intuitive and human-centered environment meets cutting-edge medicine to provide members with exceptional, personalized care that empowers them to take control of their health. We continuously incorporate new research into our method to remain on the cutting edge of medicine, and are committed to giving each of our members exceptional service with an emphasis on human-centered design throughout their Biograph journey. Follow Biograph on X and LinkedIn.
About Caristo Diagnostics
Caristo Diagnostics (www.caristo.com) is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo's award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Caristo already received FDA 510(k) clearance for its CaRi-Plaque technology, which quantifies coronary plaque and stenosis based on CCTA scans. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention. For more information, visit caristo.com. Find Caristo online on LinkedIn, YouTube, Instagram, and X.
Photo - https://mma.prnewswire.com/media/2784299/Biograph_Caristo_Diagnostics.jpg
Logo - https://mma.prnewswire.com/media/2784777/Biograph_X_Caristo_Logo.jpg
SOURCE Caristo Diagnostics
Share this article